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Abstract
Background: Placental malaria (PM) is associated with adverse pregnancy outcomes including low birth weight (LBW).
However, the precise mechanisms by which PM induces LBW are poorly defined. Based on the essential role of angiopoietin
(ANG)-1 and -2 in normal placental vascular development, we hypothesized that PM may result in the dysregulation of
angiopoietins and thereby contribute to LBW outcomes.
Methods and Findings: In a mouse model of PM, we show that Plasmodium berghei ANKA infection of pregnant mice
resulted in dysregulated angiopoietin levels and fetal growth restriction. PM lead to decreased ANG-1, increased ANG-2, and
an elevated ratio of ANG-2/ANG-1 in the placenta and the serum. These observations were extended to malaria-exposed
pregnant women: In a study of primigravid women prospectively followed over the course of pregnancy, Plasmodium
falciparum infection was associated with a decrease in maternal plasma ANG-1 levels (P=0.031) and an increase in the ANG-
2:ANG-1 ratio (P=0.048). ANG-1 levels recovered with successful treatment of peripheral parasitemia (P=0.010). In a cross-
sectional study of primigravidae at delivery, angiopoietin dysregulation was associated with PM (P=0.002) and LBW
(P=0.041). Women with PM who delivered LBW infants had increased ANG-2:ANG-1 ratios (P=0.002) compared to
uninfected women delivering normal birth weight infants.
Conclusions: These data support the hypothesis that dysregulation of angiopoietins is associated with PM and LBW
outcomes, and suggest that ANG-1 and ANG-2 levels may be clinically informative biomarkers to identify P. falciparum-
infected mothers at risk of LBW deliveries.
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Introduction
Low birth weight (LBW) infants have increased rates of
mortality during the first year of life [1,2]. Placental malaria
(PM) due to Plasmodium falciparum infection doubles the risk of
LBW, and results in an estimated 100 000 infant deaths per year
[3]. Despite a clear association of LBW with PM and high
mortality rates, the mechanisms by which malaria infection of the
placenta induces LBW are poorly defined.
PM-associated LBW is a result of intrauterine growth restriction
(IUGR) and/or premature delivery (,37 weeks of gestation) [4].
Both IUGR and spontaneous preterm delivery can result from
functional placental insufficiency [5-8] where nutrient supply is
inadequate to support fetal growth and continued in utero
development. A key factor associated with placental insufficiency
is the abnormal formation of the vascular network within the
placenta [9,10]. A complex interplay of angiogenic factors is
required for formation of normal placental villous vasculature.
Angiopoietins (ANG-1 and ANG-2) are critical regulators of
vascular development and angiogenesis. The placental and
systemic expression levels of ANG-1 and ANG-2 in normal and
pathological pregnancy has been explored in numerous studies
[11–20]. In situ hybridization and immunohistochemical studies of
human placentas have identified the syncytiotrophoblast and
cytotrophoblasts as sources of ANG-1 and ANG-2, and placental
macrophages and endothelial cells as sources of ANG-2
[11,13,15,18,19,21]. ANG-1 promotes vascular maturation while
ANG-2 destabilizes the vasculature and promotes angiogenesis. In
concert with vascular endothelial growth factor (VEGF), the
angiopoietins have been proposed to guide fetal trophoblast
invasion of the uterine wall and spiral artery remodeling at mid-
gestation (16–20 weeks), as well as drive the continuous vascular
remodeling required to sustain fetal growth in the third trimester
[18,20]. Abnormal expression of other angiogenic factors, VEGF
and its soluble receptor sFlt1, has been associated with PM in first
time mothers at delivery [22].
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vascular endothelium. The constitutive interaction of ANG-1 with
Tie-2 maintains the integrity and quiescent nature of the mature
vascular enthothelium [23,24]. As ANG-2 is an antagonist of ANG-
1/Tie-2 interactions, its expression is under tight regulation. Both
TNF and VEGF are able to induce endothelial cell ANG-2
transcription and de novo proteinexpression [25,26]. ANG-2 is also
stored in endothelial intracellular vesicles, termed Weibel-Palade
bodies, that can be rapidly released upon endothelial activation
[27]. Recently, increased circulating ANG-2 levels were associated
with severe and cerebral malaria in three distinct populations [28–
30], while ANG-1 levels and the ratio of ANG-2/ANG-1 were
shown to differentiate between individuals with cerebral malaria
and those with uncomplicated malaria, in addition to predicting
mortality in Ugandan children with cerebral malaria [29].
Based on the observations that angiopoietins play an important
role in pregnancy and are dysregulated with severe and cerebral
malaria, we hypothesized that angiopoietin dysregulation also
occurs with PM, and that this contributes to LBW outcomes
associated with PM. To test this hypothesis, we examined
angiopoietin levels in an experimental PM mouse model and in
malaria-exposed pregnant women. We report that altered
angiopoietin levels are associated with PM and LBW.
Materials and Methods
Ethics Statement
Studies of pregnant women were approved by the Institutional
Review Board, Georgetown University; the National Ethical
Committee, Ministry of Public Health, Cameroon; and the National
Institutes of Health. Written or verbal consent was obtained from
each study participant: Written informed consent was obtained
when women were able to read the consent form, otherwise
documented verbal consent was obtained (i.e., a third party (usually
a friend of the participant) signed that the woman had consented).
This consentapproachwasspecificallyapproved byallreview bodies
due to the high number of illiterate women in the study region.
Mouse experiments were approved by the University Health
Network Animal Care Committee and performed in accordance
with current institutional and national regulations, including the
Canadian Council on Animal Care’s Guide to the Care and Use of
Experimental Animals and the Ontario Society for the Prevention of
Cruelty to Animals Act. Mice were maintained on a 12-hr dark
and 12-hr light cycle with free access to feed and water.
Murine Placental Malaria Model
Eight to ten week-old BALB/c mice were obtained from
Jackson Laboratories (Bar Harbor, ME). Experimental PM was
induced by infecting pregnant BALB/c females with Plasmodium
berghei ANKA as previously described [31]. Briefly, female mice
were mated with males, and checked daily for the presence of
a vaginal plug (gestational day 1 (G1)). Cryopreserved P. berghei
ANKA (MR4; Manassas, VA) was thawed and passaged through
male BALB/c mice. Upon confirmation of pregnancy by
observation of 3–4 g body weight increase, pregnant females were
infected on G13 with 10
6 P. berghei-infected erythrocytes in RPMI
media via injection into the lateral tail vein. Control pregnant
females were injected with the same volume of RPMI media alone.
Parasitemia was monitored daily by thin blood smear stained with
modified Giemsa stain (Protocol Hema3 Stain Set, Sigma, Oakville,
ON). Pregnant female mice were euthanized by CO2 on days 16, 18
or 19 post-conception, (i.e., days 3, 5 or 6 post infection/control
injection). Blood was collected by cardiac puncture, centrifuged
(13,000 rpm for 5 minutes), and serum stored at 280uCu n t i l
analyzed. Uteri were removed and examined for evidence of
resorptions (necrotic bodies and scarring). Yolk sacs were dissected
from uteri, fetuses were removed and weighed, and placentas were
snap frozen and stored at 280uC until analyzed. Fetal viability was
determined by assessing pedal withdrawal reflex. Non-viable fetuses
(i.e., lacking the pedal withdrawal reflex) were considered aborted.
Placenta qRT-PCR for ANG-1 and ANG-2
RNA was extracted from snap-frozen placentas after homog-
enization in TRIzol (1 mL/100 mg tissue; Invitrogen, Burlington,
ON) according to manufacturer’s protocol. Extracted RNA (2 mg
per sample) was treated with DNase I (Ambion, Streetsville, ON)
and reverse transcribed to cDNA with SuperScript III (Invitrogen,
Burlington, ON) in the presence of oligo(dT)18 primers (Fermen-
tas, Burlington, ON). Residual RNA was degraded with RNase H
(Invitrogen, Burlington, ON). Sample cDNA was amplified in
triplicate with SYBR Green master mix (Roche, Laval, QC) in the
presence of 1 mM both forward and reverse primers in a Light
Cycler 480 (Roche, Laval, QC). Transcript number was calculated
based on Ct as compared to a standard curve of mouse genomic
DNA included on each plate by Light Cycler 480 software (Roche,
Laval, QC), and normalized by geometric averaging of GAPDH
and HPRT expression levels as previously described [32]. Primer
sequences (59–39): ANGPT1, F-CCTCTGGTGAATATTGG-
CTTGGGA, R-AGCATGTACTGCCTCTGACTGGTT; AN-
GPT2, F-AGAGTACTGGCTGGGCAATGAGTT, R-TTCCC-
AGTCCTTCAGCTGGATCTT; GAPDH, F-TCAACAGCA-
ACTCCCACTCTTCCA, R-TTGTCATTGAGAGCAATGC-
CAGCC; HPRT, F-GGAGTCCTGTTGATGTTGCCAGTA,
R-GGGACGCAGCAACTGACATTTCTA.
Placenta Western Blots
Snap-frozen placentas were homogenized in RIPA buffer
[150 mM NaCl, 1% NP40, 0.5% deoxycholate, 0.1% SDS,
50 mM TRIS-HCl, pH 8.0, containing complete protease in-
hibitor cocktail (Roche, Laval, QC)] at a ratio of 10 mL buffer/mg
tissue. Homogenates were incubated on ice for 30 minutes then
centrifuged (10,0006g, 10 minutes, 4uC) twice, transferring the
supernatant to a fresh tube between centrifugation steps.
Placental lysate protein (10 mg) was heated to 100uC for 5
minutes in denaturing loading buffer, centrifuged (10,0006g,5
minutes), electrophoresed on 10% SDS-PAGE gel, then trans-
ferred to PVDF membrane. Membranes were blocked [Tris
buffered saline (TBS) containing 0.05% (v/v) Tween-20 and 5%
(w/v) milk powder] for 1 hour at room temperature. Membranes
were incubated overnight at 4uC in blocking buffer containing
mouse anti-b actin (AC-40, 1:10,000; Sigma, Oakville, ON) and
rabbit polyclonal anti-angiopoietin-1 (1:1000; Abcam, Cambridge,
MA) or rabbit polyclonal anti-angiopoietin-2 (1:500; ADI, San
Antonio, TX). Membranes were washed [TBS containing 0.05%
(v/v) Tween-20] for 3610 minutes and incubated with HRP-
conjugated anti-rabbit-IgG and anti-mouse-IgG antibodies
(BioRad, Mississauga, ON) for 1 hour at room temperature.
Signal was developed by a 2-minute incubation with SuperSignal
West Picoluminescent substrate (Pierce, Rockford, IL); membranes
were exposed to autoradiation film, which was developed with
a medical film processor (Konica Minolta, Wayne, NJ). The
amount of angiopoietin protein in placentas was quantified by
densitometry using Scion Image 4.0.3.2 (Scion, Frederick, MD)
and expressed normalized to the density of the actin band.
Mouse Serum Angiopoietin-1 Measurement
The mouse and human ANG-1 protein sequences are 97%
homologous; therefore, we measured mouse serum ANG-1 levels
ANGs in Placental Malaria
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titration of recombinant peptide corresponding to amino acids 20-
128 of mouse ANG-1 (Primm, Cambridge, MA) was used to gauge
the specificity to mouse ANG-1, and was appropriately detected
by the human reagents. Serum ANG-1 concentration was
determined by comparison to the human ANG-1 recombinant
protein standard curve included on each plate.
Human Study Participants and Plasma Samples
A cohort of pregnant women was prospectively followed over
the course of pregnancy in Yaounde ´ and Ngali II, Cameroon
during 2001–2004 [33]. Peripheral plasma samples were collected,
thin and thick blood smears were prepared, and clinical history,
including antimalarial use and malaria symptoms, were obtained
at up to seven monthly visits per woman spanning all three
trimesters of pregnancy. Peripheral parasitemia was determined
from thick and thin blood smears of samples stained with Diff-
Quik (Baxter Scientific, Miami, FL) and examined for the presence
of P. falciparum. Women who were blood-smear positive for P.
falciparum were prescribed antimalarial treatment according to the
Cameroon Ministry of Health’s policy. In addition, peripheral
plasma samples, thin and thick blood smears, intervillous space
(IVS) blood and placental impression smears were collected at
delivery, and infant weight was recorded. PM was defined as the
detection of P. falciparum parasites in IVS blood smears and in
impression smears of placental tissue.
Samples from all study participants who satisfied the following
inclusion criteria were tested: primigravidae with live singleton
birth, minimum of three peripheral plasma samples from different
gestation points available for testing, and PM infection status
determined at delivery. The characteristics of the study partici-
pants analyzed for angiopoietin levels are presented in Table 1.
To further evaluate the association of angiopoietin levels with
LBW outcomes in a different study design and population,
peripheral blood samples and paired placental blood samples
collected from the IVS, were selected from a cross-sectional study
conducted in Yaounde ´, Cameroon during 1995–2001 [34].
Peripheral parasitemia was determined from thick and thin blood
smears of samples stained with Diff-Quik (Baxter Scientific,
Miami, FL) and examined for the presence of P. falciparum.P M
was defined as detection of P. falciparum parasites in thick and thin
blood smears of IVS blood and impression smears of placental
tissue. Plasma samples were stored at 280uC.
Samples (n=177) were selected based on the following criteria:
consecutively enrolled primigravid women with PM delivering live
singleton neonates with LBW (,2500 g) or normal birth weight
(NBW; $2500 g). Control groups of consecutive women without
PM who delivered live NBW or LBW singleton babies were also
included in the study. The characteristics of these study
participants are presented in Table 2.
Plasma Angiopoietin Level Measurements
Plasma levels of ANG-1 and ANG-2 were measured by enzyme
immunoassay using the appropriate antibody pair and standard
duosets (R&D, Minneapolis, MN). Plasma samples were diluted
1:10 (ANG-1) or 1:5 (ANG-2).
Statistical Analyses
Two-way ANOVA tests with Bonferonni post-tests or t-tests
(unpaired for normally distributed data, and Mann-Whitney for
non-normally distributed data) were conducted as appropriate for
mouse experiments. A mixed linear multivariate model was
applied to the prospective study sample results, with gestational
age and presence of peripheral parasites as fixed variables, and
study participant as a random variable. Pairwise analysis of
angiopoietin levels upon resolution of parasitemia was performed
by paired t-test. Cross-sectional study ANG-1 and ANG-2 levels
were analyzed by Mann-Whitney test. ANG-2/ANG-1 ratio
values were log-transformed to achieve a normal distribution then
analyzed by unpaired t-test (with Welch’s correction for unequal
variances, where applicable). Statistical analyses were performed
using Prism 4.03 (GraphPad Software, La Jolla, CA) and/or SPSS
(Chicago, IL).
Results
Spontaneous Abortion and IUGR in Experimental
Placental Malaria Model
We used an experimental mouse model to replicate the adverse
fetal outcomes of PM in primigravid women [31]. Naturally mated
BALB/c females were infected on gestational day (G) 13 via
intravenous injection of 10
6 P. berghei-infected erythrocytes
obtained from a BALB/c passage mouse. Control pregnant
females received an intravenous injection of RPMI media on G13.
Litters of injected pregnant females were analyzed at G16 (3 days
post injection (D3); n=5 uninfected and n=5 infected), at G18
(D5; n=4 uninfected and n=5 infected) and at G19 (D6; n=10
uninfected and n=13 infected). By G19/D6, the viability rate of
fetuses from infected pregnant BALB/c females was only 3466%,
in contrast to 95615% for fetuses from uninfected controls
(P,0.001; Fig. 1A). Control values are in agreement with the fetal
viability originally reported at G18 for this model [31]. In our
hands, the majority of non-resorbed G18 fetuses were viable,
regardless of infection status.
Table 1. Characteristics of subjects from prospective study population tested for angiopoietin levels.
Aparasitemic Parasitemic P
Number of participants 81 5
Age (years)
a 22.564.4 20.564.6 0.243
b
Number (%) with placental P. falciparum at delivery 0 (0%) 8 (53%) 0.019
c
Gestational age at delivery (weeks)
a 41.061.5 38.463.2 0.041
d
Birth weight (g)
a 30316446 28436378 0.293
d
aMean 6 SD.
bMann-Whitney test.
cFisher’s exact test.
dUnpaired t-test.
doi:10.1371/journal.pone.0009481.t001
ANGs in Placental Malaria
PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9481Malaria infection also affected the weight of the developing
fetuses. At G19, the mean weight of viable fetuses from infected
pregnant BALB/c females was lower than that of viable fetuses
from uninfected mice (P,0.0001; Fig. 1B). In contrast, G18 fetuses
from both groups had comparable weights. Fetuses from un-
infected mice gained 31615% extra weight between G18 and G19
(P,0.0001), while viable fetuses from infected mice showed no
growth over the same period of time (P=0.903; Fig. 1B). Thus, we
were able to recapitulate two main adverse birth outcomes
associated with PM – spontaneous abortion and IUGR – with this
experimental mouse model.
Angiopoietin Levels Are Altered in Experimental PM
In order to test the hypothesis that PM is associated with
dysregulation of the angiogenic factors ANG-1 and ANG-2,
quantitative real-time PCR (qRT-PCR) of Angpt1 and Angpt2 genes
was performed on cDNA transcribed from placental RNA. Since
we were also interested in the timing of angiogenic dysregulation
in relation to the observed fetal growth restriction, we examined
placentas of viable fetuses at G18 (i.e., precluding fetal growth
restriction, n=5 placentas from 3 uninfected and 3 infected mice)
and G19 (i.e., after onset of growth restriction, n=10 placentas
from 7 uninfected mice, n=8 placentas from 4 infected mice).
Transcription of Angpt2 and the ratio of Angpt2/Angpt1 was
significantly increased in placentas of infected mice (2-way
ANOVA: infection, P=0.0063 and P=0.0031, respectively;
Fig. 2), and Angpt1 showed a trend towards decreased expression
in placentas of infected as compared to uninfected mice (2-way
ANOVA: infection, P=0.056). Marked angiopoietin ratio dysre-
gulation was observed at G18 (Fig. 2C), prior to the observation of
IUGR.
To determine if malaria infection also altered the placental
angiopoietin protein levels, semi-quantitative Western blots of
lysates from placentas of viable G19 fetuses were performed (Fig. 3;
n=11 placentas from 8 uninfected mice, n=14 placentas from 6
infected mice). We also examined a random selection of placentas
from pregnant mice euthanized at earlier times (G16/D3 n=8
placentas from 4 uninfected mice, n=8 placentas from 5 infected
Table 2. Characteristics of cross-sectional study participants tested for angiopoietin levels.
PM- NBW PM- LBW PM+ NBW PM+ LBW
Number of participants 47 44 51 35
Age (years) 22.265.0 21.264.7 20.964.3 20.463.7
Placental parasitemia (% of erythrocytes parasitized) 0 0 6.0613.8 6.5615.3
Gestational age at delivery (wks) 38.962.4 35.864.0 * 39.263.2 34.963.8 ** 1
Birth weight (g) 31666413 20226415 ** 31206404 19776429 ** 1
Number of preterm deliveries 8 (16%) 26 (59%) *** 10 (20%) 24 (69%) *** ‘
Dunn’s multiple comparison test: *P,0.01 cp to PM- NBW;
**P,0.001 cp to PM- NBW;
1P,0.05 cp to PM+ NBW;
Fisher’s exact test: *** P,0.0001 cp to PM- NBW;
‘P,0.0001 cp to PM+ NBW.
doi:10.1371/journal.pone.0009481.t002
Figure 1. Experimental model recapitulates the spontaneous abortion and low birth weight outcomes characteristic of PM. (A)
Pregnant BALB/c females infected (dark bars) with P. berghei on gestational day (G)13 have an increased rate of abortion and decreased proportion of
viable pups per litter compared to uninfected mice (light bars) by G19, day 6 of infection/control injection (D6). Proportion of viable fetuses depicted
by solid bars; aborted fetuses, by striped bars. (B) Body weight of viable fetuses is decreased with maternal malaria infection (dark symbols) as
compared to weight of fetuses from uninfected mice (light symbols). Dots are individual viable fetuses; bars represent the median of each group. 20–
83 fetuses were collected per group (from 4–13 pregnant females per group). *** P,0.001 (Mann-Whitney).
doi:10.1371/journal.pone.0009481.g001
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placentas from 5 infected mice). Both ANG-1 and ANG-2 levels
changed with gestational time, regardless of infection (2-way
ANOVA: P,0.01 and P,0.001, respectively). In the case of
ANG-1, the mean level increased with time, which is consistent
with reports that Angpt1 mRNA levels in the placenta increase
throughout human pregnancy [18]. An increase in mean
uninfected placental ANG-1 expression was observed between
G18 and G19 (0.32 to 0.80, P=0.008); however, this increase was
absent in the placentas of the infected mice over the same time
(0.45 to 0.51, P=0.691; Fig. 3A). At G19, the placentas of infected
mice showed a trend towards less ANG-1 than those of uninfected
mice (0.51 vs 0.80, P=0.053; Fig. 3A). The mean level of ANG-2
declined with the course of pregnancy, also paralleling what occurs
in human pregnancy at the RNA and protein levels [18]. In
contrast to the unchanged mean level of ANG-2 in the placentas of
uninfected mice from G16 to G18, the mean ANG-2 levels in
placentas of infected mice was almost two-fold higher at G18/D5
as compared to G16/D3 (0.29 vs 0.18, P=0.006; Fig. 3B). At
G18/D5, the placentas of P. berghei-infected pregnant mice had
increased mean ANG-2 levels compared those from uninfected
mice (0.29 vs 0.21, P,0.01, Fig. 3B).
These results show that the placentas of viable but low weight
fetuses resulting from experimental PM are associated with
dysregulated angiopoietin expression at both transcript and
protein levels, and this dysregulation precedes the observed
malaria-associated fetal growth restriction. Taken together, these
data support the hypothesis that malaria infection-associated
angiopoietin dysregulation could play a pathophysiological role in
growth restriction.
While information on angiopoietin levels within the placenta
provides the most relevant data on pregnancy outcomes, we also
investigated whether systemic levels of angiopoietins are altered, as
has been reported in humans with cerebral and severe malaria
[29,30]. We used an immunoassay to determine if circulating
maternal peripheral blood ANG-1 levels were similarly altered
during experimental PM. Serum ANG-1 levels were significantly
decreased at G18/D5 and G19/D6 in infected pregnant mice
compared to uninfected pregnant mice (2-way ANOVA: (infection
6gestational age) interaction, P,0.001; Fig. 4). We were unable
to measure serum ANG-2 levels in the mice due to an absence of
antibodies against native mouse ANG-2.
Angiopoietin Levels Are Altered in Pregnant Women
Infected with P. falciparum
We next extended our observations from the mouse model to
malaria-exposed pregnant women. We measured ANG-1 and
ANG-2 levels in peripheral plasma of 23 primigravid women who
were followed prospectively throughout gestation (Fig. 5). 15 of the
23 (62.3%) women were blood-smear positive for P. falciparum at
least once over the course of pregnancy (Table 1). ANG-1 levels
were significantly decreased in the plasma of women when they
were blood-smear positive compared to when they were blood-
smear negative (Fig. 5B, C vs 5A). When we accounted for the
gestational age with a multivariate analysis, presence of peripheral
parasitemia was associated with a decrease of 7.3 ng/mL in mean
plasma ANG-1 levels (P=0.031). The mean plasma level in
aparasitemic pregnant women was 18.8614.4 ng/mL.
Likewise, infection with P. falciparum increased the ANG-
2:ANG-1 ratio by 0.328 units (P=0.048). The mean plasma
ANG-2:ANG-1 ratio in aparasitemic women was 0.42660.588.
We observed a decline in plasma ANG-2 levels in the last two
trimesters ($14 weeks gestation), as has been previously reported
[16]; P. falciparum infection did not appear to significantly alter this
trend (P=0.434).
Women with detected peripheral parasitemia were prescribed
antimalarial chemotherapy, and several resolved their peripheral
infection by the following visit. These events occurred at different
gestational ages in different individuals. Pairwise analysis of
normalized peripheral plasma angiopoietin levels at these two
points (parasitemic followed by aparasitemic) revealed a significant
increase in normalized ANG-1 levels with parasite clearance
regardless of when parasitemia occurred in gestation (P=0.010;
Fig. 6A). A trend towards decreased ANG-2/ANG-1 upon
Figure 2. Placental Angpt2 mRNA expression is increased by malaria infection (P=0.0063, 2-way ANOVA). (A) Angpt1 and (B) Angpt2
transcripts were measured by real-time quantitative PCR using cDNA templates reverse transcribed from placental RNA from pregnant mice
uninfected (light bars) and infected with P. berghei (dark bars). Copy number was normalized to housekeeping gene expression as described in
Materials and Methods. (C) The relative expression of Angpt2/Angpt1 is also increased in placentas associated with viable fetuses of infected mice
(P=0.0032, 2-way ANOVA on log-transformed data). Dots are individual placentas associated with viable fetuses; bars represent the median of each
group. 4–6 mice are represented per group. *P,0.01 (Bonferonni post-test). D, day post infection/control injection; G, gestational day.
doi:10.1371/journal.pone.0009481.g002
ANGs in Placental Malaria
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did not reach statistical significance (P=0.232; Fig. 6B). These
results show that P. falciparum infection of pregnant women is
associated with systemic, and reversible, angiopoietin dysregulation.
Since only a small number of women (n=2) in this study
delivered LBW babies, it was not possible to determine if the
observed angiopoietin dysregulation was also associated with LBW
outcomes.
Angiopoietin Dysregulation at Delivery Is Associated with
PM and LBW
To extend our observations to a different population and study
design, and to further explore the hypothesis that angiopoietin
dysregulation is associated with the LBW outcome observed in
PM, we tested the plasma ANG-1 and ANG-2 levels from
primigravidae with PM (PM+) at delivery who had normal birth
weight (NBW) or LBW infants, and compared them to plasma
levels from primigravidae who were PM-negative (PM-) and
delivered NBW or LBW infants (Table 2).
Peripheral ANG-1 levels were similar in all groups of women
with the exception of the PM- women who delivered LBW infants.
Consistent with the decreased ANG-1 found in association with
malaria infection in the experimental PM model and the
prospective cohort, PM+ women who delivered LBW infants
had decreased peripheral ANG-1 levels compared to PM- women
who delivered LBW infants (P=0.002; Fig. 7A).
PM was associated with elevated maternal peripheral ANG-2
levels in primigravid women at delivery of both NBW (P=0.0171)
and LBW (P,0.0001) infants as compared to the PM- NBW
group (Fig. 7B). The placental plasma ANG-2 levels were 2-9
times higher than matched peripheral ANG-2 levels (data not
shown), suggesting that the source of systemic angiopoietin levels is
the placenta. PM- women who delivered LBW infants also showed
an increase in ANG-2, however, as they also had increased ANG-1
levels, their ANG-2:ANG-1 ratio was only modestly higher in this
group as compared to the PM- NBW group (Fig. 7C).
When the four groups were analyzed together by 2-way
ANOVA, the ANG-2:ANG-1 ratio was significantly increased by
both PM (P=0.002) and LBW outcomes (P=0.041). A significant
increase in the ANG-2:ANG-1 ratio was found in the peripheral
plasma of women in the PM+ LBW group as compared to both
the PM- NBW (P=0.002) and PM- LBW (P=0.017). In support
of the hypothesis that both PM and LBW are associated with
increased angiopoietin dysregulation, the ANG-2:ANG-1 ratio
showed a trend towards being higher in the PM+ women at
delivery of LBW infants as compared to NBW infants. However,
this difference was just beyond statistical significance (P=0.063),
Figure 4. Malaria infection decreases maternal serum ANG-1 in
pregnant mice (P ,0.001, 2-way ANOVA). Serum ANG-1 levels
from uninfected (light bars) and P. berghei infected (dark bars) pregnant
mice as measured by ELISA. Dots are individual mice; bars represent the
median of each group. *** P,0.001 (Bonferonni post-test). D, day post
infection/control injection; G, gestational day.
doi:10.1371/journal.pone.0009481.g004
Figure 3. Placental ANG-1 and ANG-2 protein levels are dysregulated by malaria infection. (A) ANG-1 and (B) ANG-2 protein levels in
placentas from pregnant mice uninfected (light bars) and infected with P. berghei (dark bars). Protein levels were detected by Western blot, quantified
by densitometry and normalized to intensity of b-actin bands. Dots are individual placentas associated with viable fetuses; bars represent the median
of each group. 3–13 mice are represented per group. **P,0.01, ‘ P=0.053 (unpaired t-test). D, day post infection/control injection; G, gestational
day.
doi:10.1371/journal.pone.0009481.g003
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(P=0.056). A similar trend was observed in the ANG-2:ANG-1
ratio of placental plasma samples (Fig. 7D).
A proportion of the LBW infants were delivered prior to 37
weeks of gestation (i.e., preterm delivery; Table 2). However, no
difference in the maternal peripheral plasma ANG-2:ANG-1 levels
was observed when stratified based on gestational age at delivery
(,37 vs $37 weeks; P=0.424, Mann-Whitney test). Furthermore,
a lack of correlation between the ANG-2:ANG-1 ratio at delivery
and the length of gestation (Spearman coefficient=-0.1672,
P=0.1666) suggests the changes in maternal angiopoietin levels
at delivery of LBW infants we observed in this cohort (Fig. 7C)
cannot be fully explained by premature delivery.
Previous reports have shown an age effect with respect to host
response to PM [22]; however, there was no significant difference
between angiopoietin levels when stratified by maternal age (#20
vs .20 years; ANG-1, P=0. 298; ANG-2, P=0.289; ratio,
P=0.143).
Taken together, these results show that the relative expression of
ANG-1 and ANG-2 at delivery is altered in the context of PM, and
that more marked dysregulation of angiopoietins is associated with
LBW outcomes.
Figure 5. The presence of peripheral parasitemia during pregnancy correlates with decreased plasma ANG-1 levels (P=0.031,
mixed linear model). (A) Peripheral plasma ANG-1 levels (6 SEM) for uninfected primigravid women who had no detectable peripheral or placental
parasitemia during the course of the study (n=8). (B & C) Peripheral plasma ANG-1 levels from two representative primigravid women with PM. The
mean levels for uninfected women are shown as reference (in light shade). Boxed data points represent visits where women were peripheral blood-
smear positive for P. falciparum.
doi:10.1371/journal.pone.0009481.g005
Figure 6. Angiopoietin-1 levels are increased upon resolution of peripheral parasitemia. Paired peripheral plasma (A) ANG-1 and (B) ANG-
2/ANG-1 levels of primigravid women at consecutive visits: the first, when parasitemic by peripheral blood smear microscopy, and the next, when
successfully treated and blood-smear negative. To account for physiological variation in angiopoietin levels with gestational age, values were
normalized to mean value of aparasitemic controls at the corresponding gestational age. n=13 pairs. ** P,0.01,
‘ P.0.05 (paired t-test).
doi:10.1371/journal.pone.0009481.g006
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This study provides the first evidence associating dysregulation
of angiopoietins with PM and LBW outcomes. With the objective
of providing a plausible mechanistic link between PM and LBW,
we examined the expression of the angiogenic factors ANG-1 and
ANG-2 in a mouse PM model as well as in two cohorts of malaria-
exposed pregnant women. ANG-1 and its antagonist, ANG-2,
interact with the same receptor, Tie-2, to regulate endothelial
activation and vascular remodeling. Their relative levels provide
an indication of the state of endothelial quiescence or activation,
with an elevated ANG-2:ANG-1 ratio reflecting active remodeling
of the endothelium [35,36]. This study provides evidence of
increased ANG-2:ANG-1 ratio with PM infection, and shows an
association between dysregulated angiopoietins and LBW.
We observed a significant decrease in ANG-1 expression with
malaria infection during the course of pregnancy in both the mouse
model and pregnant women (Figs. 3A, 4, 5, 7A). Similarly,
a significant increase in ANG-2 was observed in both the mouse
PM model (Figs. 2B, 3B) and in the primigravid women with PM at
delivery (Fig. 7B). Elevation of the ANG-2:ANG-1 ratio with PM
was also consistently observed (Figs. 2C, 7C). Observed differences
in individual angiopoietin levels between the human study cohorts
likely reflect differing study designs (prospective vs. cross-sectional)
and the dynamic expression levels of angiopoietins during gestation.
Ourresults support the hypothesis that angiopoietin dysregulationis
associated with PM, and that more marked angiopoietin dysregula-
tion is associated with LBW outcomes.
Our findings that dysregulated angiopoietin levels are associated
with poor pregnancy outcomes are supported by similar findings in
Figure 7. Plasma angiopoietin levels at delivery are dysregulated in PM and with LBW outcomes. (A–C) Peripheral plasma and (D)
matched placental plasma obtained at delivery of normal birth weight (NBW) or LBW infants from primigravid women with (PM+) or without (PM-)
PM were measured for ANG-1 and ANG-2 by ELISA. (A) Mean maternal peripheral plasma ANG-1 is elevated with LBW deliveries in PM- but not PM+
women. Statistical analyses by Mann-Whitney test. (B) Maternal peripheral plasma ANG-2 is elevated with PM. Statistical analyses by Mann-Whitney
test. (C) Elevated maternal peripheral plasma ANG-2/ANG-1 ratio at delivery is associated with PM (P=0.0016) and LBW (P=0.0406); 2-way ANOVA on
log-transformed data. Statistical analyses between groups by t-test on log-transformed data. (D) Placental plasma ANG-2/ANG-1 ratio levels are
elevated compared to peripheral plasma levels. Statistical analysis by t-test on log-transformed data. Dots represent individual women, lines
represent the median of each group. Peripheral plasma, PM- NBW (n=47), PM- LBW (n=44), PM+ NBW (n=51), PM+ LBW (n=35). Placental plasma,
PM- NBW (n=41), PM- LBW (n=34), PM+ NBW (n=44), PM+ LBW (n=28). * P,0.05, ** P,0.01, *** P,0.001, # P=0.06,
‘ P=0.486.
doi:10.1371/journal.pone.0009481.g007
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IUGR and preterm delivery to which PM has been compared [37]:
An increased ratio of systemic ANG-2:ANG-1 in the second trimester
has been associated with the development of preeclampsia [12].
Studies using Doppler ultrasound have shown that placental
blood flow is altered with malarial infection during pregnancy, and
that abnormal uterine artery flow velocity waveforms can develop
even late in pregnancy [38,39]. A decline of ANG-2 in the later
part of pregnancy is important to facilitate the switch from
branching angiogenesis, which is mediated by synergism of ANG-
2 and VEGF [40], to nonbranching angiogenesis, which is
required for efficient nutrient and gas exchange [17] and would
affect placental blood flow. A failure to make this switch has been
shown to be associated with IUGR [41]. Thus, an ANG-2 level
that is either too high or sustained too late in gestation could result
in formation of a placental vasculature that is inefficient in
supporting the full growth potential of the fetus. The elevated
ANG-2 levels we observed in primigravid PM+ women supports
this hypothesis (Fig. 7B), whereby sustained elevated ANG-2 levels
persisting late in gestation could contribute to sprouting of more
vessels rather than elongation and terminal differentiation of
existing ones. In agreement with these findings, the placental
vascular architecture has been reported to have more numerous
fetal blood vessels with malaria infection [42]. Histopathology on
placentas from the experimental PM model has also been reported
to show vascular abnormalities [31].
Given the roles already ascribed to ANG-2, and the known
mechanisms associated with PM, it is tempting to hypothesize that
ANG-2 is a key mediator of pathology in PM. Placental parasitized
erythrocytes are known to bind chondroitin sulfate A expressed on
the syncytiotrophoblast, thus sequestering in the intervillous space
[43,44]. Products from burst parasitized erythrocytes within the
intervillous space can stimulate macrophages and the syncytio-
trophoblast to generate C5a, TNF and other inflammatory
cytokines and chemokines [45-48], which in turn contribute to
the macrophage infiltration associated with LBW outcomes of PM
[49]. In such an inflammatory milieu, activated syncytiotropho-
blast and macrophages could secrete ANG-2, as immunhisto-
chemical studies have shown both cell types express ANG-2
[13,18]. Inappropriately timed stimulation of endothelial cells to
proliferate and migrate may then prevent appropriate vascular
formation required to support the developing fetus.
ANG-2 has also been shown to sensitize endothelium to the
effects of TNF [50]. TNF is one of the few factors associated with
PM that has been shown to mediate pathology. An increase of TNF
in placental plasma of PM+ women has been shown in several
studies [42,51–53], and the role of TNF as a mediator of fetal loss
associated with placental malaria has been directly demonstrated by
TNF-blocking experiments in Plasmodium-infected pregnant mice
[54,55] and non-human primates [56]. An increased ANG-2
expression in response to malaria infection may explain in part why
pregnant mice infected with low dose of P. vinkei required an
injection of only 1.5 mg recombinant human TNF to induce fetal
loss, while uninfected pregnant mice could withstand 50 mg TNF
without any fetal loss [55]. It will be informative in future
experiments to test TNF in parallel with ANG-2 and ANG-1,
and, in the mouse model, determine if the effect of elevated TNF is
abrogated in the absence of elevated ANG-2.
The P. berghei/BALB/c model of PM used in this study
recapitulates the severe clinical outcomes that make human PM
a global health priority: spontaneous abortion and fetal growth
restriction, as reproduced in this study (Fig. 1), and preterm
delivery [31]. Using such a model offers several advantages for
more precise mapping of the complex host-parasite interaction
that mediates adverse pregnancy outcomes in PM. These include
the ability to control the timing of infection, the inoculum, the
timing of data collection, and the opportunity to dissect the
contribution of genetic determinants to outcome using modified
mouse strains and immunological interventions. Collectively these
make the mouse PM model a powerful tool to help understand the
pathogenesis of PM, particularly if the findings in the PM model
can be linked to clinically relevant outcomes, as we have shown in
this study with respect to angiopoietin dysregulation and LBW
outcomes.
A limitation of this study is the large proportion of LBW
outcomes in the cross-sectional study that were attributable to
preterm deliveries (,37 weeks; Table 2). Preterm delivery and
IUGR have been suggested to be associated with acute and chronic
placental malaria infections, respectively [57]. However, both
preterm delivery and IUGR can result from placental insufficiency
and inadequate blood flow delivery to the fetus [5–7]. In support of
preterm delivery and IUGR being defined pathologies along
a continuum of poor fetal growth, IUGR has been associated with
a higher risk of spontaneous preterm delivery [8,58]. We did not
observe any significantdifferenceinthe maternalangiopoietin levels
at delivery between women delivering preterm LBW infants and
those delivering LBW infants at full term. As such, PM-induced
angiopoietin dysregulation may be informative for differentiating
LBW infants regardless of etiology. This could have significant
clinical relevance as LBW itself is associated with increased infant
mortality regardless of gestational age [59].
Based on this study, we cannot exclude the possibility that
angiopoietin dysregulation is a consequence of PM but not a cause
of fetal growth restriction. Further studies in the mouse PM model
involving blocking of ANG-2 or supplementing with ANG-1 will
be required to prove causality. Nonetheless, our results suggest
that ANG-2:ANG-1 ratio may be informative as a biomarker in
screening for those at risk for LBW outcomes. Detection of PM
infection is difficult when relying solely on peripheral blood smears
due to the propensity of parasites to sequester in the placental
intervillous space. Currently, there is no way to distinguish those
infected pregnant women at risk of poor fetal outcomes. Thus,
a reliable biomarker of PM would be invaluable. Larger
prospective studies are required to determine whether malaria-
associated angiopoietin dysregulation could predict a LBW out-
come, if certain points in gestation are more susceptible to
infection-mediated angiopoietin dysregulation, and if dysregula-
tion at different points in gestation lead to different outcomes (i.e.,
spontaneous abortion vs. preterm delivery vs. IUGR).
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